MarketsandMarkets Next-Gen Bioprocessing Global Virtual Conference (Time zone: CET)

3rd - 4th November 2022
CONFERENCE SPEAKERS
Advisors
Dimitrios A. Lamprou
Dimitrios A. Lamprou
Professor (chair) of Biofabrication and Advanced Manufacturing,
Queen’s University Belfast


Dimitrios Lamprou (Ph.D. MBA) is Professor & Programme MSc Director at the School of Pharmacy, Queen's University Belfast (UK). Is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 120 peer-reviewed publications, has over 300 conference abstracts, has given over 120 Invited Talks in institutions and conferences across the world, and has secure Funding in excess of £2.5M. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. Dimitrios expertise is in Emerging Biopharmaceutical & Pharmaceutical Technologies in the manufacturing of Drug Delivery Systems & Medical Implants.


Speakers
Dimitrios A. Lamprou
Dimitrios A. Lamprou
Professor (chair) of Biofabrication and Advanced Manufacturing,
Queen’s University Belfast


Dimitrios Lamprou (Ph.D. MBA) is Professor & Programme MSc Director at the School of Pharmacy, Queen's University Belfast (UK). Is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 120 peer-reviewed publications, has over 300 conference abstracts, has given over 120 Invited Talks in institutions and conferences across the world, and has secure Funding in excess of £2.5M. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. Dimitrios expertise is in Emerging Biopharmaceutical & Pharmaceutical Technologies in the manufacturing of Drug Delivery Systems & Medical Implants.


John Maher
John Maher
Scientific Founder and Chief Scientific Officer,
Leucid Bio


Dr John Maher is the scientific founder and chief scientific officer of Leucid Bio. He is also a clinical immunologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of second generation (CD28) CAR technology while a visiting fellow at Memorial Sloan Kettering Cancer Center, an approach that has achieved clinical impact in haematological malignancies. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells, with a primary emphasis on solid tumour types. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.


Oliver Spadiut
Oliver Spadiut
Associate Professor,
TU Wien



Paula Meleady
Paula Meleady
Associate Director,
National Institute for Cellular Biotechnology


Principal Investigator at National Institute for Cellular Biotechnology and an Assistant Professor in the School of Biotechnology, Dublin City University.

Research interests are in the area of Biopharmaceutical Research of CHO cells where she uses proteomic characterisation of recombinant mammalian cells (Chinese hamster ovary (CHO) cells) in order to gain insights to improving productivity of biopharmaceuticals. This involves the analysis of CHO cells under varying bioprocess relevant conditions in order to identify targets that will be used to genetically engineer CHO cells to produce recombinant product (e.g. monoclonal antibodies) more efficiently. She also has particular expertise in the analysis of cellular post-translational modifications (e.g. phosphorylation, ubiquitination, etc.) that play important roles in bioprocess-relevant phenotypes such as growth and productivity

Co-author of over 100 peer-reviewed publications, has edited one book, and co-authored 13 book chapters to date in research areas related to proteomics, bioprocessing and cancer.


Pedro Silva Couto
Pedro Silva Couto
Post-Doctoral Research Fellow,
University College London


Pedro Silva Couto is a post-doctoral research fellow at University College London (UCL). His role is part of a European consortium focused on CAR-T cell manufacturing named Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital (AIDPATH). Pedro previously completed his PhD under the supervision of Dr. Qasim Rafiq at UCL. His work focused on the manufacturing of ex vivo gene therapy and extracellular vesicles using human mesenchymal stromal cells (hMSCs) for clinical applications. Pedro received a Master’s in Biochemical Engineering from IST, Portugal.  


Quentin Vicard
Quentin Vicard
Director of Product Management,
Ori Biotech



Andrew Splevins
Andrew Splevins
Senior Development Director, CMC,
Evox Therapeutics Ltd


Andrew is a Senior CMC Development Director within Evox Therapeutics responsible for the Vector Development and Supply, Cell Line Development and Analytical Development functions. Andrew joined Evox Therapeutics in 2020 to progress the development of exosome drug products. Here he continues his passion for developing novel therapeutics and solving the associated challenges. Prior to Evox, Andrew spent 9 years at Ipsen Bioinnovation working on R&D of novel recombinant botulinum neurotoxins in a variety of different roles encompassing analytical, formulation and process development. Andrew was a significant contributor to publications on the practices and pitfalls of the historical potency measurements of traditional botulinum toxin products and need for standardisation. Andrew began his industry career within cGMP Analytical Development and QC testing of biotherapeutics at Patheon and Covance. Andrew holds a PhD in Structural Biology and an MChem from the University of Sheffield.


Joseph M. Roig
Joseph M. Roig
Associate Technical Director, Apheresis | Global MSAT Cell Therapy Development and Operations,
Bristol Myers Squibb


JOSEPH M. ROIG obtained his BSc in Science of Chemistry in 1980 (University of Barcelona) and started his professional career at Coulter-Beckman, working in blood cell counting and flow cytometry. He joined COBE BCT (Terumo BCT) in 1991 to help the company start operations in Spain, moving to the US to continue working for them in 2000. During the years that he worked for COBE/Terumo BCT he was involved with all existing apheresis variants (donor collections, leukapheresis, therapeutic apheresis). He joined the Terumo BCT Scientific Support group in 2012 and the Medical Affairs group in 2016, the same year he got a Masters in Transfusion Medicine and Advanced Cell Therapies (EMTACT) by the Autonomous University of Barcelona. He became an independent apheresis consultant in 2019 and consulted for several cell & gene therapy companies including CRISPR Therapeutics, BioNTech, BlueBird Bio, PACT Pharma, Editas and Aruvant. He started working for Bristol Myers Squibb in 2020 as the Associate Technical Director of Apheresis for Global MS&T.


Itai Benhar
Itai Benhar
Professor,
Tel Aviv University


Itai Benhar—Full Professor at the Shmunis School of Biomedicine and Cancer Research and Director of the Tel Aviv University for Combatting Pandemics. Prof. Benhar received in 1992 a PhD in Molecular Biology from the Hebrew University, Israel. Between 1992-1995, he was a post-doctoral fellow at the National Cancer Institute, NIH, working with Dr. Ira Pastan on recombinant immunotoxins. This was Prof. Benhar’s introduction to the fields of cancer research and targeted immunotherapy, in which he has been active ever since.

Prof. Benhar is an expert in the fields of antibody engineering, drug discovery and drug delivery with over 27 years of being active in these fields. His research is currently focused on: 1) evaluation of novel formats of bispecific antibodies as potential therapeutic agents. 2) Antibody discovery for treating cancer, allergy, inflammation and viral infections. 3) Targeted nanomedicines.

Prof. Benhar published >110 articles, 12 book chapters, and 19 patents.


David Wood
David Wood
Professor,
The Ohio State University


David Wood is a professor of Chemical Engineering at the Ohio State University and is a co-founder and Chief Scientific Officer at Protein Capture Science.  David completed a double major in Biology and Chemical Engineering at Caltech, followed by a Ph.D. in Chemical Engineering at RPI, and worked in the biopharmaceutical industry at Amgen and BMS before starting his career in academia.  His research focuses on protein engineering for practical applications in health science and has included novel biosensors and fusion proteins.  Over the past 25 years he has developed intein technology with the goal of creating a viable, disruptive technology for the biopharma industry, and is a key inventor on this technology and its associated patents.


Rohan Kamat
Rohan Kamat
Head R&D division,
Immuneel Therapeutics


Rohan Kamat obtained his PhD in Molecular Virology from The Tata Memorial Centre’s Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai, India, where he developed viral vectors for gene therapy. After a brief post doctoral fellowship in Neurobiology at NCBS, Bangalore, Rohan ventured into entrepreneurship where he founded Viravecs Labs and Straximm Therapeutics.

Currently Rohan heads the R&D division at Immuneel Therapeutics in Bangalore, India. Immuneel works on making cellular immune-therapies affordable to India and the sub-population. Immuneel’s first asset in clinical trails is a CD19 targeting CAR-T cell therapy for leukaemias and lymphomas.